Krystal Biotech will present at the J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco.
Quiver AI Summary
Krystal Biotech, Inc. announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Krish S. Krishnan will present on January 12, 2026, at 10:30 am ET. The presentation will be available via webcast on the company's website, and Krishnan will also hold investor meetings throughout the day. Krystal Biotech, based in Pittsburgh, focuses on developing genetic medicines for diseases with significant unmet needs, and its first product, VYJUVEK®, is the first redosable gene therapy approved in multiple regions for dystrophic epidermolysis bullosa. The company is advancing a diverse pipeline of investigational therapies across various medical fields.
Potential Positives
- Participation in a prestigious event like the J.P. Morgan Healthcare Conference highlights the company's visibility and engagement within the biotech industry.
- The scheduled presentation by the Chairman and CEO provides an opportunity to communicate the company's advancements and strategic direction directly to investors.
- The announcement reiterates the company's status as a commercial-stage biotechnology firm, emphasizing its commitment to addressing high unmet medical needs with innovative genetic therapies.
- Introduction of VYJUVEK®, a breakthrough in gene therapy, positions Krystal Biotech as a leader in the field and may enhance investor confidence in its product pipeline and future growth.
Potential Negatives
- None
FAQ
When is Krystal Biotech participating in the J.P. Morgan Healthcare Conference?
Krystal Biotech will participate in the conference on January 12, 2026.
Who will represent Krystal Biotech at the conference?
Krish S. Krishnan, Chairman and CEO, will represent the company.
What time will Krystal Biotech's presentation start?
The presentation is scheduled to start at 10:30 am ET / 7:30 am PT.
Where can I watch the presentation?
The presentation will be available as a webcast on the company's website.
What is the focus of Krystal Biotech's work?
Krystal Biotech focuses on developing genetic medicines for diseases with high unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRYS Insider Trading Activity
$KRYS insiders have traded $KRYS stock on the open market 62 times in the past 6 months. Of those trades, 0 have been purchases and 62 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- KRISH S KRISHNAN (President and CEO) has made 0 purchases and 31 sales selling 100,000 shares for an estimated $18,525,282.
- SUMA KRISHNAN (President, R&D) has made 0 purchases and 31 sales selling 100,000 shares for an estimated $18,525,168.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KRYS Hedge Fund Activity
We have seen 152 institutional investors add shares of $KRYS stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 602,428 shares (+1743.1%) to their portfolio in Q3 2025, for an estimated $106,346,614
- BRAIDWELL LP removed 207,410 shares (-28.5%) from their portfolio in Q3 2025, for an estimated $36,614,087
- PRICE T ROWE ASSOCIATES INC /MD/ added 205,675 shares (+78.7%) to their portfolio in Q3 2025, for an estimated $36,307,807
- GOLDMAN SACHS GROUP INC removed 182,111 shares (-34.3%) from their portfolio in Q3 2025, for an estimated $32,148,054
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 170,858 shares (+72.9%) to their portfolio in Q3 2025, for an estimated $30,161,562
- MILLENNIUM MANAGEMENT LLC added 136,151 shares (+1083.8%) to their portfolio in Q3 2025, for an estimated $24,034,736
- CAPITAL WORLD INVESTORS removed 133,009 shares (-14.1%) from their portfolio in Q3 2025, for an estimated $23,480,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KRYS Analyst Ratings
Wall Street analysts have issued reports on $KRYS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 10/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Chardan Capital issued a "Buy" rating on 08/05/2025
To track analyst ratings and price targets for $KRYS, check out Quiver Quantitative's $KRYS forecast page.
$KRYS Price Targets
Multiple analysts have issued price targets for $KRYS recently. We have seen 5 analysts offer price targets for $KRYS in the last 6 months, with a median target of $220.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $220.0 on 11/04/2025
- Yigal Nochomovitz from Citigroup set a target price of $198.0 on 11/04/2025
- Alec Stranahan from B of A Securities set a target price of $255.0 on 10/17/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $240.0 on 09/15/2025
Full Release
PITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company’s website .
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® , the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
[email protected]
